{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["hepatitis", "in silico", "molecular dynamics", "new drugs", "plant compounds", "terpenoids", "treatment"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37375532", "DateRevised": {"Year": "2023", "Month": "07", "Day": "01"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "06", "Day": "18"}], "Language": ["eng"], "ELocationID": ["842", "10.3390/pathogens12060842"], "Journal": {"ISSN": "2076-0817", "JournalIssue": {"Volume": "12", "Issue": "6", "PubDate": {"Year": "2023", "Month": "Jun", "Day": "18"}}, "Title": "Pathogens (Basel, Switzerland)", "ISOAbbreviation": "Pathogens"}, "ArticleTitle": "Discovery of Terpenes as Novel HCV NS5B Polymerase Inhibitors via Molecular Docking.", "Abstract": {"AbstractText": ["Hepatitis C virus (HCV) is a dangerous virus that is responsible for a large number of infections and deaths worldwide. In the treatment of HCV, it is important that the drugs are effective and do not have additional hepatotoxic effects. The aim of this study was to test the in silico activity of 1893 terpenes against the HCV NS5B polymerase (PDB-ID: 3FQK). Two drugs, sofosbuvir and dasabuvir, were used as controls. The GOLD software (CCDC) and InstaDock were used for docking. By using the results obtained from PLP.Fitness (GOLD), pKi, and binding free energy (InstaDock), nine terpenes were finally selected based on their scores. The drug-likeness properties were calculated using Lipinski's rule of five. The ADMET values were studied using SwissADME and pkCSM servers. Ultimately, it was shown that nine terpenes have better docking results than sofosbuvir and dasabuvir. These were gniditrin, mulberrofuran G, cochlearine A, ingenol dibenzoate, mulberrofuran G, isogemichalcone C, pawhuskin B, 3-cinnamyl-4-oxoretinoic acid, DTXSID501019279, and mezerein. Each docked complex was submitted to 150 ns-long molecular dynamics simulations to ascertain the binding stability. The results show that mulberrofuran G, cochlearine A, and both stereoisomers of pawhuskin B form very stable interactions with the active site region where the reaction product should form and are, therefore, good candidates for use as effective competitive inhibitors. The other compounds identified in the docking screen either afford extremely weak (or even hardly any) binding (such as ingenol dibenzoate, gniditrin, and mezerein) or must first undergo preliminary movements in the active site before attaining their stable binding conformations, in a process which may take from 60 to 80 ns (for DTXSID501019279, 3-cinnamyl-4-oxoretinoic acid or isogemichalcone C)."]}, "AuthorList": [{"Identifier": ["0000-0001-6599-9204"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chair and Department of Medical Microbiology, Pozna\u0144 University of Medical Sciences, Rokietnicka 10, 60-806 Pozna\u0144, Poland."}], "LastName": "Karpi\u0144ski", "ForeName": "Tomasz M", "Initials": "TM"}, {"Identifier": ["0000-0003-2305-3116"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biotechnology, Institute of Natural Fibres and Medicinal Plants-National Research Institute, Wojska Polskiego 71b, 60-630 Pozna\u0144, Poland."}], "LastName": "O\u017carowski", "ForeName": "Marcin", "Initials": "M"}, {"Identifier": ["0000-0001-9316-9275"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "FP-I3ID/Fac. de Ci\u00eancias da Sa\u00fade, Universidade Fernando Pessoa, 4200-150 Porto, Portugal."}, {"Identifier": [], "Affiliation": "UCIBIO@REQUIMTE, BioSIM, Departament of Biomedicine, Faculty of Medicine, Universidade do Porto, 4200-319 Porto, Portugal."}], "LastName": "Silva", "ForeName": "Pedro J", "Initials": "PJ"}, {"Identifier": ["0000-0002-4859-5360"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research Group of Medical Microbiology, Chair and Department of Medical Microbiology, Pozna\u0144 University of Medical Sciences, Rokietnicka 10, 60-806 Pozna\u0144, Poland."}], "LastName": "Stasiewicz", "ForeName": "Mark", "Initials": "M"}, {"Identifier": ["0000-0001-9415-9386"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biological Solution Centre (BioSol Centre), Farmgate, Dhaka 1215, Bangladesh."}], "LastName": "Alam", "ForeName": "Rahat", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biological Solution Centre (BioSol Centre), Farmgate, Dhaka 1215, Bangladesh."}], "LastName": "Samad", "ForeName": "Abdus", "Initials": "A"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Pathogens", "NlmUniqueID": "101596317", "ISSNLinking": "2076-0817"}, "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Irekeola A.A., Ear E.N.S., Mohd Amin N.A.Z., Mustaffa N., Shueb R.H. Antivirals against HCV Infection: The Story Thus Far. J. Infect. Dev. Ctries. 2022;16:231\u2013243. doi: 10.3855/jidc.14485.", "ArticleIdList": ["10.3855/jidc.14485", "35298416"]}, {"Citation": "Salari N., Kazeminia M., Hemati N., Ammari-Allahyari M., Mohammadi M., Shohaimi S. Global Prevalence of Hepatitis C in General Population: A Systematic Review and Meta-Analysis. Travel Med. Infect. Dis. 2022;46:102255. doi: 10.1016/j.tmaid.2022.102255.", "ArticleIdList": ["10.1016/j.tmaid.2022.102255", "35007756"]}, {"Citation": "Hepatitis C.  [(accessed on 13 October 2022)].  Available online:  https://www.who.int/news-room/fact-sheets/detail/hepatitis-c."}, {"Citation": "El-Kassas M., Awad A. Metabolic Aspects of Hepatitis C Virus. World J. Gastroenterol. 2022;28:2429\u20132436. doi: 10.3748/wjg.v28.i22.2429.", "ArticleIdList": ["10.3748/wjg.v28.i22.2429", "PMC9258278", "35979265"]}, {"Citation": "Karpi\u0144ski T.M. The Microbiota and Pancreatic Cancer. Gastroenterol. Clin. N. Am. 2019;48:447\u2013464. doi: 10.1016/j.gtc.2019.04.008.", "ArticleIdList": ["10.1016/j.gtc.2019.04.008", "31383281"]}, {"Citation": "Zhou Z., Zhang J., Zhou E., Ren C., Wang J., Wang Y. Small Molecule NS5B RdRp Non-Nucleoside Inhibitors for the Treatment of HCV Infection: A Medicinal Chemistry Perspective. Eur. J. Med. Chem. 2022;240:114595. doi: 10.1016/j.ejmech.2022.114595.", "ArticleIdList": ["10.1016/j.ejmech.2022.114595", "35868125"]}, {"Citation": "Zaj\u0105c M., Muszalska I., Sobczak A., Dadej A., Tomczak S., Jeli\u0144ska A. Hepatitis C\u2014New Drugs and Treatment Prospects. Eur. J. Med. Chem. 2019;165:225\u2013249. doi: 10.1016/j.ejmech.2019.01.025.", "ArticleIdList": ["10.1016/j.ejmech.2019.01.025", "30685524"]}, {"Citation": "Dash D.K., Tyagi C.K., Sahu A.K., Tripathi V., Dash D.K., Tyagi C.K., Sahu A.K., Tripathi V. Revisiting the Medicinal Value of Terpenes and Terpenoids. IntechOpen; London, UK: 2022."}, {"Citation": "Cox-Georgian D., Ramadoss N., Dona C., Basu C. Therapeutic and Medicinal Uses of Terpenes. Med. Plants. 2019:333\u2013359. doi: 10.1007/978-3-030-31269-5_15.", "ArticleIdList": ["10.1007/978-3-030-31269-5_15"]}, {"Citation": "Al-Salihi S.A.A., Alberti F. Naturally Occurring Terpenes: A Promising Class of Organic Molecules to Address Influenza Pandemics. Nat. Prod. Bioprospect. 2021;11:405\u2013419. doi: 10.1007/s13659-021-00306-z.", "ArticleIdList": ["10.1007/s13659-021-00306-z", "PMC8090910", "33939136"]}, {"Citation": "Chatow L., Nudel A., Nesher I., Hayo Hemo D., Rozenberg P., Voropaev H., Winkler I., Levy R., Kerem Z., Yaniv Z., et al. In Vitro Evaluation of the Activity of Terpenes and Cannabidiol against Human Coronavirus E229. Life. 2021;11:290. doi: 10.3390/life11040290.", "ArticleIdList": ["10.3390/life11040290", "PMC8065867", "33805385"]}, {"Citation": "Astani A., Schnitzler P. Antiviral Activity of Monoterpenes Beta-Pinene and Limonene against Herpes Simplex Virus in Vitro. Iran. J. Microbiol. 2014;6:149\u2013155.", "ArticleIdList": ["PMC4393490", "25870747"]}, {"Citation": "Wo\u017aniak \u0141., Sk\u0105pska S., Marsza\u0142ek K. Ursolic Acid--A Pentacyclic Triterpenoid with a Wide Spectrum of Pharmacological Activities. Molecules. 2015;20:20614\u201320641. doi: 10.3390/molecules201119721.", "ArticleIdList": ["10.3390/molecules201119721", "PMC6332387", "26610440"]}, {"Citation": "Kong L., Li S., Liao Q., Zhang Y., Sun R., Zhu X., Zhang Q., Wang J., Wu X., Fang X., et al. Oleanolic Acid and Ursolic Acid: Novel Hepatitis C Virus Antivirals That Inhibit NS5B Activity. Antivir. Res. 2013;98:44\u201353. doi: 10.1016/j.antiviral.2013.02.003.", "ArticleIdList": ["10.1016/j.antiviral.2013.02.003", "23422646"]}, {"Citation": "Jones G., Willett P., Glen R.C., Leach A.R., Taylor R. Development and Validation of a Genetic Algorithm for Flexible Docking. J. Mol. Biol. 1997;267:727\u2013748. doi: 10.1006/jmbi.1996.0897.", "ArticleIdList": ["10.1006/jmbi.1996.0897", "9126849"]}, {"Citation": "Mohammad T., Mathur Y., Hassan M.I. InstaDock: A Single-Click Graphical User Interface for Molecular Docking-Based Virtual High-Throughput Screening. Brief. Bioinform. 2021;22:bbaa279. doi: 10.1093/bib/bbaa279.", "ArticleIdList": ["10.1093/bib/bbaa279", "33105480"]}, {"Citation": "Hang J.Q., Yang Y., Harris S.F., Leveque V., Whittington H.J., Rajyaguru S., Ao-Ieong G., McCown M.F., Wong A., Giannetti A.M., et al. Slow Binding Inhibition and Mechanism of Resistance of Non-Nucleoside Polymerase Inhibitors of Hepatitis C Virus. J. Biol. Chem. 2009;284:15517\u201315529. doi: 10.1074/jbc.M808889200.", "ArticleIdList": ["10.1074/jbc.M808889200", "PMC2708848", "19246450"]}, {"Citation": "Xiao W., Wang D., Shen Z., Li S., Li H. Multi-Body Interactions in Molecular Docking Program Devised with Key Water Molecules in Protein Binding Sites. Molecules. 2018;23:2321. doi: 10.3390/molecules23092321.", "ArticleIdList": ["10.3390/molecules23092321", "PMC6225211", "30208655"]}, {"Citation": "Trott O., Olson A.J. AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading. J. Comput. Chem. 2010;31:455\u2013461. doi: 10.1002/jcc.21334.", "ArticleIdList": ["10.1002/jcc.21334", "PMC3041641", "19499576"]}, {"Citation": "Pokhrel S., Bouback T.A., Samad A., Nur S.M., Alam R., Abdullah-Al-Mamun M., Nain Z., Imon R.R., Talukder M.E.K., Tareq M.M.I., et al. Spike Protein Recognizer Receptor ACE2 Targeted Identification of Potential Natural Antiviral Drug Candidates against SARS-CoV. Int. J. Biol. Macromol. 2021;191:1114\u20131125. doi: 10.1016/j.ijbiomac.2021.09.146.", "ArticleIdList": ["10.1016/j.ijbiomac.2021.09.146", "PMC8474879", "34592225"]}, {"Citation": "Appleby T.C., Perry J.K., Murakami E., Barauskas O., Feng J., Cho A., Fox D., Wetmore D.R., McGrath M.E., Ray A.S., et al. Viral Replication. Structural Basis for RNA Replication by the Hepatitis C Virus Polymerase. Science. 2015;347:771\u2013775. doi: 10.1126/science.1259210.", "ArticleIdList": ["10.1126/science.1259210", "25678663"]}, {"Citation": "Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv. Drug. Deliv. Rev. 2001;46:3\u201326. doi: 10.1016/S0169-409X(00)00129-0.", "ArticleIdList": ["10.1016/S0169-409X(00)00129-0", "11259830"]}, {"Citation": "Daina A., Michielin O., Zoete V. SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules. Sci. Rep. 2017;7:42717. doi: 10.1038/srep42717.", "ArticleIdList": ["10.1038/srep42717", "PMC5335600", "28256516"]}, {"Citation": "Pires D.E.V., Blundell T.L., Ascher D.B. PkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J. Med. Chem. 2015;58:4066\u20134072. doi: 10.1021/acs.jmedchem.5b00104.", "ArticleIdList": ["10.1021/acs.jmedchem.5b00104", "PMC4434528", "25860834"]}, {"Citation": "Krieger E., Vriend G. YASARA View\u2014Molecular Graphics for All Devices\u2014from Smartphones to Workstations. Bioinformatics. 2014;30:2981\u20132982. doi: 10.1093/bioinformatics/btu426.", "ArticleIdList": ["10.1093/bioinformatics/btu426", "PMC4184264", "24996895"]}, {"Citation": "Krieger E., Vriend G. New Ways to Boost Molecular Dynamics Simulations. J. Comput. Chem. 2015;36:996\u20131007. doi: 10.1002/jcc.23899.", "ArticleIdList": ["10.1002/jcc.23899", "PMC6680170", "25824339"]}, {"Citation": "Maier J.A., Martinez C., Kasavajhala K., Wickstrom L., Hauser K.E., Simmerling C. Ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from Ff99SB. J. Chem. Theory Comput. 2015;11:3696\u20133713. doi: 10.1021/acs.jctc.5b00255.", "ArticleIdList": ["10.1021/acs.jctc.5b00255", "PMC4821407", "26574453"]}, {"Citation": "Essmann U., Perera L., Berkowitz M.L., Darden T., Lee H., Pedersen L.G. A Smooth Particle Mesh Ewald Method. J. Chem. Phys. 1995;103:8577\u20138593. doi: 10.1063/1.470117.", "ArticleIdList": ["10.1063/1.470117"]}, {"Citation": "Berendsen H.J.C., Postma J.P.M., van Gunsteren W.F., DiNola A., Haak J.R. Molecular Dynamics with Coupling to an External Bath. J. Chem. Phys. 1984;81:3684\u20133690. doi: 10.1063/1.448118.", "ArticleIdList": ["10.1063/1.448118"]}, {"Citation": "Jakalian A., Bush B.L., Jack D.B., Bayly C.I. Fast, Efficient Generation of High-Quality Atomic Charges. AM1-BCC Model: I. Method. J. Comput. Chem. 2000;21:132\u2013146. doi: 10.1002/(SICI)1096-987X(20000130)21:2<132::AID-JCC5>3.0.CO;2-P.", "ArticleIdList": ["10.1002/(SICI)1096-987X(20000130)21:2<132::AID-JCC5>3.0.CO;2-P", "12395429"]}, {"Citation": "Jakalian A., Jack D.B., Bayly C.I. Fast, Efficient Generation of High-Quality Atomic Charges. AM1-BCC Model: II. Parameterization and Validation. J. Comput. Chem. 2002;23:1623\u20131641. doi: 10.1002/jcc.10128.", "ArticleIdList": ["10.1002/jcc.10128", "12395429"]}, {"Citation": "Dyson J.K., Hutchinson J., Harrison L., Rotimi O., Tiniakos D., Foster G.R., Aldersley M.A., McPherson S. Liver Toxicity Associated with Sofosbuvir, an NS5A Inhibitor and Ribavirin Use. J. Hepatol. 2016;64:234\u2013238. doi: 10.1016/j.jhep.2015.07.041.", "ArticleIdList": ["10.1016/j.jhep.2015.07.041", "26325535"]}, {"Citation": "Yousefsani B.S., Nabavi N., Pourahmad J. Contrasting Role of Dose Increase in Modulating Sofosbuvir-Induced Hepatocyte Toxicity. Drug. Res. 2020;70:137\u2013144. doi: 10.1055/a-1117-3004.", "ArticleIdList": ["10.1055/a-1117-3004", "32157674"]}, {"Citation": "Wahid B. Hepatotoxicity and Virological Breakthrough of HCV Following Treatment with Sofosbuvir, Daclatasvir, and Ribavirin in Patients Previously Treated for Tuberculosis. J. Med. Virol. 2019;91:2195\u20132197. doi: 10.1002/jmv.25557.", "ArticleIdList": ["10.1002/jmv.25557", "31347729"]}, {"Citation": "Bukal N., Furic-Cunko V., Juric I., Katalinic L., Dedo A., Basic-Jukic N. Severe Hepatotoxicity of Ritonavir, Ombitasvir, Paritaprevir, and Dasabuvir in a Kidney Transplant Recipient. Saudi J. Kidney Dis. Transplant. 2019;30:1184\u20131186. doi: 10.4103/1319-2442.270279.", "ArticleIdList": ["10.4103/1319-2442.270279", "31696862"]}, {"Citation": "Ejeh S., Uzairu A., Shallangwa G.A., Abechi S.E., Ibrahim M.T. In Silico Design and Pharmacokinetics Investigation of Some Novel Hepatitis C Virus NS5B Inhibitors: Pharmacoinformatics Approach. Bull. Natl. Res. Cent. 2022;46:109. doi: 10.1186/s42269-022-00796-y.", "ArticleIdList": ["10.1186/s42269-022-00796-y"]}, {"Citation": "Rehman S., Ijaz B., Fatima N., Muhammad S.A., Riazuddin S. Therapeutic Potential of Taraxacum Officinale against HCV NS5B Polymerase: In-Vitro and In Silico Study. Biomed. Pharmacother. 2016;83:881\u2013891. doi: 10.1016/j.biopha.2016.08.002.", "ArticleIdList": ["10.1016/j.biopha.2016.08.002", "27513212"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "10", "Day": "20"}, {"Year": "2023", "Month": "6", "Day": "12"}, {"Year": "2023", "Month": "6", "Day": "15"}, {"Year": "2023", "Month": "6", "Day": "28", "Hour": "6", "Minute": "43"}, {"Year": "2023", "Month": "6", "Day": "28", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "6", "Day": "28", "Hour": "1", "Minute": "33"}, {"Year": "2023", "Month": "6", "Day": "18"}], "PublicationStatus": "epublish", "ArticleIdList": ["37375532", "PMC10305183", "10.3390/pathogens12060842", "pathogens12060842"]}}], "PubmedBookArticle": []}